Netherlands and USA-based Merus has inked an exclusive licensing accord with privately-held Partner Therapeutics (PTx), for the right to commercialize zenocutuzumab (Zeno) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the USA. 2 December 2024
Switzerland-based Novocure saw its shares leap 38% to $27.64 as it revealed positive results from the pivotal, Phase III PANOVA-3 trial, demonstrating a statistically-significant improvement in median overall survival (mOS) versus control. 2 December 2024
Shares of Israel-based clinical-stage company Purple Biotech jumped 9.5% to 6.90 shekels after it announced positive final results from the randomized Phase II study of its lead oncology drug, CM24, a humanized monoclonal antibody that blocks CEACAM1, in patients with pancreatic ductal adenocarcinoma (PDAC). 2 December 2024
Berlin, Germany-based radioisotopes specialist Eckert & Ziegler Radiopharma today announced the successful start of Actinium-225 (Ac-225) production, addressing the global shortage of this critical radionuclide. 2 December 2024
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
The US Food and Drug Administration (FDA) has extended the review period for Soleno Therapeutics’ the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release tablets 27 November 2024
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Swiss drugmaker Idorsia was trading more than 10% higher by lunchtime on Wednesday. Idorsia earlier announced that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan. 27 November 2024
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Berlin, Germany-based Eckert & Ziegler Radiopharma has received approval of its proprietary non-carrier added Lutetium-177 chloride, Theralugand, by the European Commission (EC). 27 November 2024
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis that was submitted by New Jersey, USA-based Insmed. 6 February 2025
Shares in US retinal diseases specialist EyePoint Pharmaceuticals recovered from an early nosedive to close trading marginally higher on Wednesday. 6 February 2025
Kura Oncology and Japan’s Kyowa Kirin have announced that their menin inhibitor ziftomenib met the primary endpoint in a Phase II trial for relapsed or refractory acute myeloid leukemia (AML) 6 February 2025
US clinical-stage biotech Qlaris Bio has announced positive top-line results from two U.S. Phase II clinical trials investigating QLS-111 in patients with primary open angle glaucoma (POAG) and ocular hypertension (OHT). 6 February 2025
The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. 6 February 2025
Affinia Therapeutics, a US biotech with a pipeline of rationally designed adeno-associated virus (AAV) gene therapies for cardiovascular and neurological diseases, has announced the appointment of Hideo Makimura as its chief medical officer (CMO). 5 February 2025
In Düsseldorf, Algiax Pharmaceuticals is working on a novel analgesic which could provide an effective alternative to opioids, according to new mid-stage data. 5 February 2025
San Diego, USA-based Turnstone Biologics yesterday announced that it has completed an assessment of its business and operations, including the status of its program, resources, and capabilities. 5 February 2025
Spanish plasma-derived medicines specialist Grifols revealed it is collaborating with Dutch biotechnology start-up, FcR Therapeutics, to develop recombinant nanobodies to treat autoimmune diseases. 5 February 2025
AdvanCell announced the successful completion of an oversubscribed $112 million (US) Series C financing, making it the only Australian radiopharma company that has cash to burn. 4 February 2025
German biotech Akribion Therapeutics has emerged from stealth with 8 million euros ($9 million) in seed funding to accelerate the development of its novel RNA-guided precision medicines. 4 February 2025
Sionna Therapeutics hopes to raise $150 million and secure a market capitalization of about $692 million in an initial public offering (IPO). 4 February 2025
French drugmaker Mitem Pharma, which is dedicated to drugs of major therapeutic interest (DMTI), today revealed that has acquired the rights to Flisint (fumagillin) from pharma major Sanofi. 4 February 2025
California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be changed to BeOne Medicines) combining the latter’s lead product Tevimbra (tislelizumab), a PD-1 checkpoint inhibitor (CPI), and ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln). 3 February 2025
UK contract research organization hVIVO is gearing up to test an inhaled antiviral candidate, IN-002, for respiratory syncytial virus (RSV) in a Phase IIa human challenge trial. 3 February 2025
Blackstone, the world’s largest alternative asset manager, is expanding its presence in the life sciences sector with a new multibillion-dollar fund dedicated to drug development. 31 January 2025
Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development of risvodetinib following disappointing results from a Phase II trial of patients with untreated Parkinson's disease. 31 January 2025
CNS-focused biopharma Axsome Therapeutics has won US Food and Drug Administration (FDA) approval for Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. 31 January 2025